Keros Therapeutics (KROS) Receivables (2021 - 2025)
Keros Therapeutics' (KROS) quarterly Receivables came in at $3.6 million in Q4 2025, up 30.09% YoY from $2.7 million in Q4 2024, and up 2.15% on a QoQ basis from $3.5 million in Q3 2025.
Keros Therapeutics (KROS) Receivables (2021 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 4 years of Receivables data on file, last reported at $3.6 million in Q4 2025.
- Quarterly Receivables rose 30.09% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 30.09% YoY) and the FY2025 annual result came in at $3.6 million, up 30.09% from the prior year.
- Receivables grew to $3.6 million in Q4 2025, from $3.5 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $18.0 million in Q4 2021 to a low of $4000.0 in Q2 2024.
- A 4-year average of $5.6 million and a median of $2.7 million in 2024 frame the typical range for Receivables.
- The widest YoY moves for Receivables: up 395300.0% in 2025, down 30.09% in 2025.
- Tracing KROS's Receivables over 4 years: stood at $18.0 million in 2021, then slumped by 99.21% to $143000.0 in 2023, then jumped by 1817.48% to $2.7 million in 2024, then soared by 30.09% to $3.6 million in 2025.
- The last three Receivables figures came in at $3.6 million (Q4 2025), $3.5 million (Q3 2025), and $15.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | - |
| 10 | Keros Therapeutics | 215.82 Mn | -41.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.57 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 15.82 Mn |
| Mar 31, 2025 | 17.29 Mn |
| Dec 31, 2024 | 2.74 Mn |
| Sep 30, 2024 | 388,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 226,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Dec 31, 2021 | 18.00 Mn |
| Jun 30, 2021 | 100,000.00 |